Sunshine Heart's CEO Departs As The Firm Faces Trial Challenges
This article was originally published in The Gray Sheet
The heart-assist device firm abruptly announced the departure of its CEO. Sunshine has faced multiple challenges, including slow enrollment and the need for protocol-ordered pause, with the pivotal trial for its C-Pulse system.
You may also be interested in...
The company has switched from pursuing a counterpulsation technology to focusing on a fully implantable neuromodulation device, and is now directing its full attention to the recently acquired Aquadex FlexFlow ultrafiltration system for heart failure, all in a period of about three-to-four months.
SENZA PDN showed Nevro's HF10 spinal cord stimulation therapy provided sustained relief to patients with painful diabetic neuropathy. Results of a separate trial showed HF10 improved outcomes in patients with non-surgical refractory back pain.
No device-related warning letters were released by the US FDA the week of 19 January.